PDCD1 and cancer: The gut microbiome is also associated with clinical responses to anti-PD-1 immunotherapy in a variety of cancers (155, 157–163), however, no common overall microbial signal or metabolomic profile has been identified, even within cancers, indicating additional factors must be at play.